Consumers spent $211.5 billion online during the second quarter of 2020, with e-commerce sales up 31.8% from the previous quarter, according to figures released by the Census Bureau of the Department of Commerce. E-commerce sales in the quarter accounted for 16.1% of total retail sales.
The data showed that total retail sales decreased 3.6% in the same period.
Compared to the year-ago period, second quarter 2020 e-commerce sales increased increased 44.5% while total retail sales decreased 3.6%.
https://chainstoreage.com/e-commerce-sales-jumped-nearly-40-second-quarter-says-us-census-bureau?oly_enc_id=3347B1825112J2H&utm_source=omeda&utm_medium=email&utm_campaign=NL_CSA+Day+Breaker&utm_keyword=
Related Posts
Hello Everyone, We need your help to ensure Congress knows protecting printed package inserts (PI) is a priority! The ECL & Printed Literature Business is once again under attack from a Pharmaceutical lobbying group trying to remove the use of printed literature and other forms of extended content. As you know this is a significant threat to our industry, the good thing is that it is easy for us to start to TAKE ACTON and fight back. It is vitally important that we all support this initiative. It will take support from everyone, and everyone you know, to get the attention of our leaders in Washington DC. Below are the details on how to participate in a campaign being run by PPLA, the Pharmaceutical Printed Literature Association. This campaign is an all-out effort to protect the printed literature/ECLs produced by our all the Pharma Literature printing sites across the entire country. There has been recent movement by another lobbying group (comprised mostly of larger generic drug manufacturers) to have printed literature that is provided to pharmacists/professionals eliminated entirely…our position is that we do not oppose making the information available to professionals electronically but do oppose eliminating the paper format entirely – for 2 reasons, ensuring patient safety and protecting against job losses within the Pharma Literature/ECL Printing Industry. click read more for details...
J. C. Penney Company, Inc. announced that it has reached an agreement in principle to sell JCPenney through a court-supervised sale process. The Company plans to seek approval of a disclosure statement and, ultimately, confirmation of a plan of reorganization in parallel with the sale process. Related to the sale process, JCPenney expects to execute a “stalking horse” asset purchase agreement, which will track an executed letter of intent, outlining the following: *Brookfield Property Group and Simon Property Group intend to acquire substantially all of JCPenney’s retail and operating assets for $1.75 billion, which includes a combination of cash and new term loan debt. *The agreement contemplates the formation of a separate real estate investment trust and a property holding company, which will include 161 of the Company’s real estate assets and all of its owned distribution centers. The PropCos will be owned by the Company’s Ad Hoc Group of First Lien Lenders. *The OpCo and PropCos will enter into a master lease with respect to the properties and distribution centers moved into the PropCos.
Kohl’s Corporation (NYSE:KSS) (“Kohl’s” or the “Company”) today issued the following statement: The Kohl's Board of Directors (the Board) has determined, following a review with its independent financial advisors and upon the recommendation of its Finance Committee, that the valuations indicated in the current expressions of interest which it has received do not adequately reflect the Company’s value in light of its future growth and cash flow generation. The Board is committed to maximizing the long-term value of the Company and will review and pursue opportunities that it believes would credibly lead to value consistent with its performance and future opportunities. The Board has designated its Finance Committee to lead the ongoing review of any expressions of interest. The Finance Committee, which was formed pursuant to the 2021 settlement agreement with Macellum Advisors GP, LLC and other shareholders, is comprised exclusively of independent directors. The Company and the Board have also engaged financial advisors, including Goldman Sachs and PJT Partners, and have asked Goldman Sachs to engage with interested parties.